IMPRoving Outcomes in Vascular DisEase- Aortic Dissection
Trial ID or NCT#
NCT06087029
Status
NOT RECRUITING
Purpose
The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.
Official Title
IMPRoving Outcomes in Vascular DisEase- Aortic Dissection
Eligibility Criteria
Ages Eligible for Study: Older than 21 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
- 1. Age \> 21 years2. Stanford type B aortic dissection not involving the aorta at or proximal to the innominate artery, without rupture and/or malperfusion (renal, mesenteric, or extremity)3. Acuity: within 48 hours - 6 weeks of index admission4. Ability to provide written informed consent and comply with the protocol5. Investigator believes anatomy is suitable for TEVAR
Exclusion Criteria:
- 1. Ongoing systemic infection2. Pregnant or planning to become pregnant in the next 3 months3. Life expectancy related to non-aortic conditions \< 2 years4. Unwilling or unable to comply with all study procedures including serial imaging follow-up5. Known patient history of genetic aortopathy6. Penetrating Aortic Ulcer and Intramural hematoma7. Iatrogenic (traumatic) aortic dissection8. Prior surgery for aortic dissection
Investigator(s)
View on ClinicalTrials.gov
